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Loss of skeletal muscle mass and force aggravates
age-related sarcopenia and numerous pathologies,
such as cancer and diabetes. The AKT-mTORC1
pathway plays a major role in stimulating adult mus-
cle growth; however, the functional role of its down-
stream mediators in vivo is unknown. Here, we show
that simultaneous inhibition of mTOR signaling to
both S6K1 and 4E-BP1 is sufficient to reduce AKT-
induced muscle growth and render it insensitive to
the mTORC1-inhibitor rapamycin. Surprisingly, lack
of mTOR signaling to 4E-BP1 only, or deletion of
S6K1 alone, is not sufficient to reduce muscle hyper-
trophy or alter its sensitivity to rapamycin. However,
we report that, while not required for muscle growth,
S6K1 is essential for maintaining muscle structure
and force production. Hypertrophy in the absence
of S6K1 is characterized by compromised ribosome
biogenesis and the formation of p62-positive pro-
tein aggregates. These findings identify S6K1 as a
crucial player for maintaining muscle function during
hypertrophy.
INTRODUCTION
Better understanding of the signaling pathways that control mus-
cle cell size and function is of great importance, as there are
currently no therapeutic approaches that can prevent or reduce
muscle wasting and frailty, as seen in aging and muscular dystro-
phy. While various studies have identified important regulators of
adult skeletal muscle mass, surprisingly little is known about
how these pathways can modulate muscle force. The two major
signaling pathways regulating adult skeletal muscle mass are
the AKT-mTORC1 (Mammalian Target of Rapamycin Complex
1) (Blaauw et al., 2013; Schiaffino et al., 2013) and the myostatin/
BMP-Smad pathway (Sartori et al., 2013). Overexpression of a
constitutively active form of the serine/threonine kinase AKT, orC
This is an open access article under the CC BY-Nstimulation of Bone Morphogenic Protein (BMP) signaling, leads
to a rapid increase in protein synthesis and significant muscle
growth. Despite being regulated through the activation of different
membrane receptors, hypertrophy in both cases is significantly
reduced by treatment with rapamycin, a specific inhibitor of
mTORC1 (Bodine et al., 2001; Winbanks et al., 2013). This key
role of mTORC1 signaling in the regulation of adult muscle mass
is further supported by the fact that rapamycin blocks muscle
growthafter synergist ablation, amodel of overload-inducedmus-
cle hypertrophy (Bodine et al., 2001). Even though from these
studies it is clear that most models of adult skeletal muscle
hypertrophy are rapamycin sensitive, the key downstreammedia-
torsofmTORC1signalingand their roles in improvingmuscle force
during hypertrophy in vivo are not known.
One of the main rapamycin-sensitive downstream effectors of
mTORC1 in the stimulation of protein synthesis in various cell
types is the serine/threonine kinase p70S6K1 (S6K1). Overex-
pression of a constitutively active form of S6K1 in myotubes in-
duces hypertrophy (Rommel et al., 2001), while mice lacking
S6K1 are 20% smaller than their wild-type littermates (Pende
et al., 2000). Furthermore, overexpression of a constitutively
active form of AKT in myotubes lacking S6K1 and the closely
related p70S6K2 (S6K2) does not lead to myotube hypertrophy
at low doses of AKT activation and is rapamycin insensitive
(Ohanna et al., 2005). In addition to these results obtained in
cell culture, studies performed in human and murine muscle
identified the activation of S6K1, and its downstream target ribo-
somal protein S6, as an in vivo marker of resistance exercise in-
tensity, closely following the increase in muscle mass (Baar and
Esser, 1999; Burd et al., 2010).
Despite these results, which suggest an important role for
S6K1 in the regulation of muscle mass, S6K1/2 double-knockout
mice have a normal global translational regulation, which re-
mains sensitive to rapamycin treatment (Garelick et al., 2013;
Pende et al., 2004). Furthermore, overexpression of a domi-
nant-negative form of 50 AMP-activated protein kinase (AMPK),
which is strongly activated in S6K1/2 double-knockout mice,
completely rescued fiber size in knockout (KO) animals in vivo,
suggesting that S6K1 is not required for stimulating protein syn-
thesis and maintaining fiber size (Aguilar et al., 2007).ell Reports 17, 501–513, October 4, 2016 ª 2016 The Authors. 501
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Another potential mTORC1mediator involved in the regulation
of protein synthesis is the eIF4E-binding protein 1 (4E-BP1).
Phosphorylation of 4E-BP1 by mTORC1 leads to its dissociation
from eukaryotic initiation factor 4E (eIF4E), permitting it to bind to
eukaryotic initiation factor 4G1 (eIF4G1) and forming an active
initiation complex (eIF4F). Interestingly, knockdown of eIF4E or
overexpression of a non-phosphorylatable mutant version of
4E-BP1, i.e., with a mutation in the four mTOR phosphorylation
sites (4E-BP1-4A), is sufficient to prevent increases in cell
growth, showing the importance of the eIF4E-eIF4G1 interaction
in stimulating protein synthesis. On the role of 4E-BP1 in the
regulation of skeletal muscle mass very little is known. Overex-
pression of either wild-type 4E-BP1 or the 4E-BP1-4A mutant
did not modify myotube size (Ohanna et al., 2005), and mice
lacking both 4E-BP1 and 2 have a normal muscle weight and a
regular translational regulation (Steiner et al., 2014).
Here, we determine the relative contribution of S6K1 and
4E-BP1 in the regulation of a functional muscle hypertrophy.
Our main findings show that S6K1 is sufficient, but not required,
for rapamycin-sensitivemuscle hypertrophy. Hypertrophy due to
overexpression of AKT in muscles lacking S6K1 can occur due
to compensatory signaling of mTORC1 to 4E-BP1. Importantly,
while S6K1 is not required for muscle growth, it is necessary
for AKT-induced increases in ribosome biogenesis and muscle
force. The rapid increase in protein synthesis after AKT activation
in mice lacking S6K1 leads to the appearance of myopathic fea-
tures such as necrotic fibers, central nuclei, and p62-positive
protein aggregates. Reducing protein synthesis rates by rapa-
mycin prevents the formation of protein aggregates and induces
a smaller, yet functional hypertrophy.
Taken together, our results show that S6K1 is required for the
regulation of protein quality and muscle force, but not for
increasing skeletal muscle mass.
RESULTS
AKT-Induced Muscle Growth Can Be Mediated Both by
S6K1/2 and by mTOR Signaling to 4E-BP1
In order to identify the downstream mediators of AKT-mTORC1
during muscle hypertrophy, we first focused our attention on the
two best-characterized mTORC1 targets, S6K1/2 and 4E-BP1.
To determine the role of S6K1/2 in AKT-induced muscle hyper-
trophy, we electroporated a plasmid coding for a constitutively
active form of AKT (myr-AKT) in the tibialis anterior (TA) muscle
of wild-type, S6K1 knockout, and S6K1/2 double-knockout
mice. As can be seen in Figure 1A, the cross-sectional area of
the transfected fibers (in red) 10 days after electroporation are
significantly bigger than the surrounding non-transfected fibers.
We quantified the increase in fiber size in the three different
groups, and as can be seen in Figure 1B, both transfected and
non-transfected fibers are significantly bigger in wild-type as
compared to S6K1 and S6K1/2 knockout mice. In contrast, no
significant differences were observed in the size of transfected
or non-transfected fibers between S6K1 and S6K1/2 knockout
mice, confirming that S6K1 is the major kinase involved in the
regulation of cell size. When comparing the relative increase in
fiber size between myr-AKT-transfected and non-transfected
fibers in the various groups (Figure 1C), no significant differences502 Cell Reports 17, 501–513, October 4, 2016were observed, suggesting that S6K1 is not required for AKT-
induced fiber hypertrophy. In mice lacking S6K1, S6K2 can
compensate for the absence of S6K1 by phosphorylating ribo-
somal protein S6, as shown in the western blot in Figure 1D.
As can be seen, in mice lacking both S6K1 and S6K2 the
phosphorylation of ribosomal protein S6 is undetectable. The
fact that the transfected fibers in mice lacking S6K1 and those
lacking S6K1/S6K2 show the same level of hypertrophy sug-
gests that phosphorylation of S6 on Ser240/244 is not required
for AKT-induced fiber growth. Furthermore, using a small
interfering RNA (siRNA) approach for S6K1/2 we find that
hypertrophy also occurs when S6K is reduced in adult muscles,
therefore excluding a possible role of compensation mecha-
nisms in the global S6K1/2 KO animals (Figures 1E, 1F, S1A,
and S1B).
Can this apparently minor role of S6K1 in the regulation of fiber
size be explained by increased signaling through mTOR-depen-
dent phosphorylation of the eukaryotic translation initiation fac-
tor 4E binding protein 1 (4E-BP1)? In order to elucidate this,
we co-transfected wild-type and S6K1 KO animals with myr-
AKT and a constitutively active mutant version of 4E-BP1, in
which four mTORC1-dependent phosphorylation sites are
changed to alanines (4E-BP1-4A). As can be seen in Figure 1G,
co-expression of 4E-BP1-4A does not reduce myr-AKT-induced
hypertrophy in wild-type animals, as transfected fibers show a
116% ± 13% increase in fiber size (n = 5 muscles per group).
However, when co-transfecting myr-AKT with 4E-BP1-4A in
S6K1 KO animals, muscle hypertrophy is reduced by 61% ±
8% (Figure 1G, n = 5), showing that after AKT activation,
mTOR signaling to 4E-BP1 can indeed compensate for the
lack of S6K1 inmuscle growth. Importantly, this differential effect
of 4E-BP1-4A on fiber growth is not due to changes in its protein
stability in wild-type and the S6K1 KO mouse (Figure S1C).
S6K1 and 4E-BP1 Are Key Mediators of
Rapamycin-Sensitive Hypertrophy
In order to better understand whether rapamycin reduces hyper-
trophy in a S6K-dependent manner, we electroporated wild-type
and knockout mice with myr-AKT, while simultaneously injecting
mice intraperiteonally with 2 mg/kg body weight of rapamycin.
Muscles taken from mice treated with rapamycin showed no
phosphorylation of S6, demonstrating a proper delivery of the
drug to the muscles (Figure 2A). As can be seen in Figure 2B,
transfected fibers in the vehicle-treated muscles showed a sig-
nificant hypertrophy, which is partially prevented by rapamycin
treatment. Quantification of fiber size revealed that a significant
hypertrophy persists in rapamycin-treated wild-type mice yet is
strongly reduced by 61% ± 7% when compared to vehicle-
treated animals (Figures 2C and 2D, n = 6). This inhibitory effect
of rapamycin on fiber growth is not dose dependent (Figure S2).
To understand whether this strong reduction in fiber size of AKT-
transfected fibers after rapamycin treatment in wild-type animals
is due to a block on S6K and S6 phosphorylation, we repeated
the same experiment in S6K1 and S6K1/2 knockout mice. As
can be seen in Figures 2B–2D (n = 5), rapamycin treatment
reduced hypertrophic growth in S6K1 and S6K1/2 knockout
mice, respectively, by 73% ± 9% and 71% ± 7%. This reduction
in fiber hypertrophy is not different from that seen in wild-type
Figure 1. S6K and 4E-BP1 Phosphorylation Can Independently Mediate AKT-Induced Adult Skeletal Muscle Growth
(A) Sections taken from muscles electroporated with a plasmid coding for myr-AKT and taken out 10 days later. A significant fiber hypertrophy is found in
transfected fibers (stained for anti-HA in red, anti-laminin in green) compared to non-transfected control fibers in wild-type (left), S6K1 knockout mice (middle),
and S6K1/2 double-knockout mice (right).
(B) Cross-sectional area of myr-AKT-transfected and control non-transfected fibers (wild-type [WT]; n = 6 muscles, S6K1 KO; n = 7 muscles, S6K1/2 KO; n = 6
muscles; at least 200 fibers were counted per group, and more than 30 per muscle, *p < 0.001). Control fibers in S6K1 and S6K1/2 KO mice were significantly
smaller compared to wild-type (**p < 0.01).
(C) Fold increases of fiber size in AKT-positive fibers compared to non-transfected control fibers in the same muscle.
(D) Western blot showing the phosphorylation of S6, which persists in the S6K1 KO mice, but is completely absent in the S6K1/2 KO.
(E) Average fiber size of fibers co-transfected with myr-AKT and a siRNA for S6K1/2 or for LacZ, compared to surrounding non-transfected fibers from the same
muscle (n = 4 muscles for each group, *p < 0.001).
(F) Co-transfection of the siRNA for S6K1/2 and the plasmid coding for myr-AKT showed a 2-fold increase in transfected fibers, similar to that found in fibers co-
transfected myr-AKT and a siRNA against LacZ.
(G) Cross-sectional area of fibers co-transfected with myr-AKT and a plasmid coding for a mutant version of 4E-BP1, in which four mTORC1-dependent
phosphorylation sites are modified in alanines (4E-BP1-4A). Fiber hypertrophy is significantly reduced in S6K1 KO, but not in wild-type animals (*p < 0.01
**p < 0.05; n = 5 muscles per group).
All data represent mean ± SEM.animals, showing that rapamycin can inhibit fiber hypertrophy in
a S6K1/2-independent manner.
Considering the differential regulation of mTOR-dependent 4E-
BP1 signaling in wild-type and S6K1 KO animals, we wondered
whether rapamycin reduces muscle hypertrophy by acting on
different mTORC1 mediators in wild-type and S6K1 KO animals.
In order to answer this, we co-transfectedwild-type and S6K1KOanimals with myr-AKT and 4E-BP1-4A, while treating animals
with vehicle or rapamycin for 10days. As can be seen in Figure 2E,
rapamycin reduces fiber hypertrophy by 64% ± 10% in wild-type
animals, similar to the results obtained when electroporating only
myr-AKT (Figure 2D, n = 5), suggesting that rapamycin blocks
fiber growth independently of 4E-BP1 phosphorylation. As shown
in Figure 1G, co-transfection ofmyr-AKTwith 4E-BP1-4A in S6K1Cell Reports 17, 501–513, October 4, 2016 503
Figure 2. Rapamycin Reduces AKT-Induced Hypertrophy by Inhibiting S6K1 or 4E-BP1 Signaling
(A) Mice were electroporated with myr-AKT while being treated with rapamycin (2 mg/kg per day). As can be seen in the western blot in muscles taken out after
10 days of rapamycin treatment show an effective inhibition of the phosphorylation of S6 in wild-type and S6K1 KO animals.
(B)Representative images showing a significant reductionof hypertrophy inmyr-AKT-transfected fibers compared tonon-transfected fiberswhencomparingvehicle
(left) or rapamycin-treated mice. Also in S6K1 KO (data not shown) and S6K1/2 KO (lower images), rapamycin significantly reduced AKT-induced hypertrophy.
(C) Cross-sectional area of fibers transfected with myr-AKT compared to non-transfected surrounding fibers. Rapamycin reduces fiber hypertrophy in WT, S6K1
KO, and S6K1/2 KO animals. A significant increase in fiber size of the transfected fibers persists (*p < 0.005, n = at least 6 for each group).
(D) Fold increase in CSA of AKT-positive fibers compared to untransfected control fibers in the samemuscle show the same reduction in fiber hypertrophy in WT,
S6K1, and S6K1/2 KO mice (*p < 0.005).
(E) Ratio of fiber size between fibers co-transfected with myr-AKT and 4E-BP1-4A compared to surrounding non-transfected fibers. Rapamycin treatment
significantly reduces fiber size in co-transfected wild-type fibers, but does not in co-transfected S6K1 KO fibers (n = at least 5 muscles per group, with minimal 30
transfected fibers per muscle; *p < 0.001).
(F) Fold change in CSA of AKT-positive fibers in 4E-BP1/2 KOmice. Co-transfection of a RR-S6K1 andmyr-AKT in 4E-BP1 KOmice renders hypertrophy partially
resistant to rapamycin (n = at least 5 muscles per group, with minimal 20 transfected fibers per muscle; **p < 0.01).
All data represent mean ± SEM.
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KO animals reduces fiber hypertrophy by 61%± 8% (n = 5). Inter-
estingly, performing the same co-transfection in S6K1 KO com-
bined with a rapamycin treatment did not further reduce fiber
hypertrophy (Figure 2E).
Next, wewanted to understandwhether S6K1 and 4E-BP1 are
the only rapamycin-sensitive targets involved in AKT-induced
muscle hypertrophy. To render S6K1 and 4E-BP1 rapamycin
resistant, we used, respectively, a rapamycin-resistant mutant
plasmid of S6K1 (S6K1-RR) and 4E-BP1/2 double-knockout
mice. Double-knockout mice were used to avoid the potential
compensation by 4E-BP2 upon 4E-BP1 ablation. As can be
seen in Figure 2F, overexpression of myr-AKT in 4E-BP1/2 KO
mice leads to a significant 109% ± 9% increase in fiber size,
which is reduced by 69% ± 3% after rapamycin treatment. In
order to understand whether this reduction is due to S6K1,
S6K1-RR was transfected together with myr-AKT in 4E-BP1/2
KO animals. As shown in Figure 2F, co-transfection of S6K1-
RR does not further increase the hypertrophy found after overex-
pression of myr-AKT in 4E-BP1/2 KO mice, but it does render
hypertrophy partially resistant to rapamycin, as it is reduced by
only 38% ± 4% (n = 5 in all groups).
AKTActivation in S6K1KOMice AltersMuscle Structure
and Function
Various examples of muscle hypertrophy exist in which the in-
crease in muscle mass is not accompanied by an increase in
muscle function (Amthor et al., 2007). Considering the fact that
activation of S6K1 is linked with a functional muscle hypertrophy
in humans (Burd et al., 2010), we wondered whether it might play
a role in improving muscle function. To better assess the func-
tional role of S6K1 during muscle hypertrophy induced by AKT
activation, we generated a transgenic mouse in which AKT can
be activated in an S6K1 KO background. To obtain the Akt-
S6K1 KO mice, we crossed three different transgenic lines, i.e.,
a line expressing mlc1f-cre, a second expressing a myr-AKT-
ER with a stop sequence floxed in front, and a third line lacking
S6K1 (Figure 3A). Injection of tamoxifen in Akt-S6K1 KO mice
leads to a rapid stabilization and phosphorylation of myr-AKT-
ER and to the activation of downstream targets, such as the
phosphorylation of ribosomal protein S6 (Figure 3B). Further-
more, measurement of puromycin incorporation 24 hr after one
injection of tamoxifen showed a clear increase in protein synthe-
sis in muscles taken from Akt-cre and Akt-S6K1 KO mice, as
compared to controls (Figure 3C). Continued treatment of Akt-
cre and Akt-S6K1 KO mice for 3 weeks with tamoxifen induces
a significant hypertrophy in both fast and slow muscles (Fig-
ure 3D). Quantification of the wet weight of the gastrocnemius
muscle showed, respectively, a 55% ± 6% and 70% ± 4% in-
crease in Akt-cre and Akt-S6K1 KOmice after 3 weeks of tamox-
ifen treatment (Figures S3A and S3B, n = 8). In order to determine
muscle histology in these hypertrophic muscles, we performed a
succinate dehydrogenase and H&E staining (Figures 3E and
S3C). Although overall muscle structure appeared normal in
gastrocnemius muscles from tamoxifen-treated Akt-S6K1 KO
mice, occasional areas with muscle damage and regenerating
fibers were present (Figure 3F). Indeed, staining for embryonic
myosin heavy chain, which is only expressed in early stages of
regenerating fibers, showed various positive fibers in certainareas of Akt-S6K1 KO muscles (Figure 3G). Furthermore, there
were fibers lacking staining for eosin, indicating fiber necrosis
(Figure S3D), something very rarely observed in tamoxifen-
treated Akt-cre mice, and absent in control S6K1 KOmice. In or-
der to quantify the myopathic features in the hypertrophic mus-
cles, the total number of central nuclei per muscle section was
determined (Figure 3H, n = 8). While there was an increase in
the number of centrally nucleated fibers in the gastrocnemius
of Akt-cre mice (0.4% ± 0.1%), this number increased signifi-
cantly in Akt-S6K1 KO muscles (1.8% ± 0.6%), confirming the
presence of muscle fiber necrosis and subsequent regeneration.
Furthermore, when we examined muscle ultrastructure by elec-
tron microscopy, we found four out of 23 fibers with large empty
spaces in between individual myofibrils of KO mice (Figure S3E),
confirming the presence of occasional fibers in a pathological
state.
Considering these myopathic features in hypertrophic Akt-
S6K1 KO muscles, we asked whether muscle function was
compromised. We previously showed that the activation of
AKT for 3 weeks is sufficient to increase muscle force (Blaauw
et al., 2009). As can be seen in Figure 3I, absolute maximal
force of the gastrocnemius muscle measured in vivo increased
in both wild-type and KO mice after AKT activation. However,
when normalizing muscle force for muscle weight, a significant
decrease in muscle tension was found at all stimulation fre-
quencies in hypertrophic Akt-S6K1 KO mice and not in wild-
type animals (Figures 3J and 3K).
S6K1 Is Required for AKT-Induced Increases in
Ribosome Biogenesis
In order to better understand the reason for the decrease in
normalized muscle force in Akt-S6K1 KO muscles, despite
only a relatively small percentage of necrotic fibers, we analyzed
signaling changes in Akt-cre and Akt-S6K1 KO muscles. As can
be seen in Figure 4A, many of the known downstream targets of
Akt involved in protein synthesis, such as GSK-3b, mTOR, and
RPS6, show a similar phosphorylation or expression level in
both Akt-cre and Akt-S6K1 KO muscles after AKT activation.
However, in line with findings from our electroporation experi-
ments, phosphorylation of 4E-BP1 on Ser65 is significantly
higher in Akt-S6K1 KO than in Akt-cre muscles (Figures 4A and
4B), suggesting an increase in mTOR signaling to 4E-BP1.
Recently, a role for S6K1 has been proposed in the stimulation
of ribosome biogenesis after refeeding (Chauvin et al., 2014). An
important step in ribosome biogenesis is the S6K1-dependent
stimulation of pyrimidine synthesis by phosphorylating and acti-
vating the multifunctional enzyme CAD (carbamoyl-phosphate
synthetase 2, aspartate transcarbamoylase, dihydroorotase)
on serine 1859 (Ben-Sahra et al., 2013). In Akt-cre mice treated
for 3 weeks with tamoxifen, there is a significant increase in
CAD phosphorylation (Figure 4C, n = 6), corresponding to a
44% ± 11% increase in the ratio of RNA/DNA (Figure 4D).
Normalizing total DNA and RNA for muscle weight showed
that this is due to an increase in total RNA content, not due
to changes in DNA content (Figures S4A and S4B). Considering
the fact that 80%–85% of total RNA is ribosomal RNA,
this increase in total RNA can be considered a marker of
increased ribosome biogenesis. Interestingly, in Akt-S6K1 KOCell Reports 17, 501–513, October 4, 2016 505
Figure 3. Lack of S6K1 during Muscle Hypertrophy Alters Muscle Structure and Function
(A) Schematic representationof thegenerationof amuscle-specific inducibleAKT transgenic lineand its crossingwithS6K1KOmice,giving rise toAkt-S6K1KOmice.
(B) Immunoblot analysis of protein extracts from gastrocnemius muscle of Akt-cre and Akt-S6K1 KO mice treated with tamoxifen for 3 weeks. Tamoxifen
treatment stabilizes AKT-ER, whereas Akt-ER is undetectable in oil-treated controls. Ribosomal protein S6 is phosphorylated after AKT activation independently
of the presence of S6K1.
(C) Activation of AKT in wild-type and S6K1 KO animals leads to a significant increase in puromycin incorporation after 24 hr. Images are representative for four
individual experiments.
(D) AKT activation for 3 weeks leads to muscle hypertrophy both in fast EDL muscles, as well as in the slow soleus muscle. Each bar represents the wet weight of
muscles from tamoxifen-treated mice versus their respective controls (n = 8 for each muscle, *p < 0.005).
(E) H&E staining of muscles taken from Akt-S6K1 KO gastrocnemius muscles after oil or tamoxifen treatment.
(F) Areas showing muscle degeneration (eosin-negative fibers) and regeneration (central nuclei) are found in Akt-S6K1 KO muscles.
(G) Area of muscle showing numerous fibers expressing the embryonic myosin heavy chain isoform (red). In green the muscle lamina is stained.
(H) Number of central nuclei per section in the gastrocnemius of Akt-cre and Akt-S6K1 KOmice after 3 weeks of tamoxifen treatment (n = 8 per group, *p < 0.05).
(I) Force measurements performed in vivo show that AKT activation for 3 weeks leads to a significant increase in absolute tetanic force of the gastrocnemius
muscle in both Akt-cre and Akt-S6K1 KO mice (stimulation frequency 100 Hz, n = 12 per group, *p < 0.001, **p < 0.05).
(J)Whennormalizing force formuscleweightAkt-S6K1KOmiceshowasignificant reduction in tetanicmuscle tensionafter 3weeksof tamoxifen treatment (*p<0.001).
(K) Force-frequency curve of the normalized force in Akt-S6K1 KO mice after 3 weeks of tamoxifen treatment (n = 22 muscles per group; *p < 0.001).
All data represent mean ± SEM.
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Figure 4. S6K1 Is Required for AKT-Induced Increases in RNA Synthesis
(A) Western blots of the AKT-mTORC1 pathway performed on gastrocnemius muscle taken after 3 weeks of tamoxifen treatment (representative images of
multiple blots, n = 4 per group).
(B) Quantification of the phosphorylation of 4E-BP1 on serine 65 in Akt-cre and Akt-S6K1 shows a significant increase inmTORC1 signaling to 4E-BP1 in S6K1KO
mice (n = 4 per group, *p < 0.01).
(C) Phosphorylation of CAD on serine 1859 after 3 weeks of Akt activation.
(D) Quantification of the ratio of total RNA and total DNA in gastrocnemius muscles of Akt-cre and Akt-S6K1 after 3 weeks of tamoxifen treatment (n = 6 per group,
*p < 0.01).
(E) Amount of 18S and 28S ribosomal RNA in Akt-cre and Akt-S6K1 KO mice show a blunted increase in RNA synthesis in Akt-S6K1 KO muscles.
(F) Quantification of 28S rRNA per loaded volume (n = 4 muscles per group, *p < 0.001; **p < 0.01).
All data represent mean ± SEM.mice, activation of AKT is not able to increase phosphorylation
of CAD on Ser1859 (Figure 4C) and also no significant in-
crease in the ratio RNA/DNA is observed (Figure 4D). In orderto understand whether the increase in RNA in Akt-cre animals
corresponds to ribosomal RNA, we analyzed the changes in
18 s and 28 s rRNA. As can be seen in Figures 4E and 4F, AKTCell Reports 17, 501–513, October 4, 2016 507
activation in wild-type animals leads to a very strong increase in
both 18 s and 28 s, which is strongly compromised in Akt-S6K1
KO mice (Figures 4E, 4F, and S4C).
S6K1 Is Required for Maintaining Protein Quality during
High Rates of Muscle Growth
It has been suggested that the number of ribosomes and the
speed of translational elongation can impinge on translation fi-
delity, leading to an increase of dysfunctional proteins (Conn
and Qian, 2013; Orsolic et al., 2016). In other cell types, it
has been shown that protein aggregates that form during pro-
tein synthesis, due to translational errors and folding problems,
are positive for the scaffold protein p62 (Pankiv et al., 2007).
Interestingly, when we examine the amount of p62 in Akt-
S6K1 KO muscles, we find a more pronounced increase than
that seen in Akt-cre muscles (Figures 5A and 5B). Using an
immunohistochemistry analyses to evaluate the distribution of
this increased amount of p62, we find that p62 is distributed
homogenously in Akt-cre muscles without showing aggregates.
However, in S6K1 KO muscles we observe a very strong accu-
mulation of p62-positive aggregates in some fibers, but not all
(Figure 5C). Quantification of the number of fibers presenting
these aggregates reveals that they are present in 27% ±
0.6% of S6K1 KO fibers after 3 weeks of AKT activation (Fig-
ure 5D). Furthermore, fiber-type analyses showed that they
are mainly found in a subset of type IIB fibers (Figure S5). These
results are in line with the previous finding in which some but
not all fibers showed a compromised ultrastructure (Fig-
ure S3B). In order to understand whether these aggregates
are due to the high rate of protein synthesis and can be linked
to the reduction of muscle tension, we treated mice for 3 weeks
with tamoxifen, while reducing protein synthesis rate by co-
treating mice with rapamycin. As can be seen in Figure 6A, ra-
pamycin reduces, but does not prevent the increase in protein
synthesis in Akt-S6K1 KO mice after 3 weeks of AKT activation,
leading to a significant increase in the muscle weight/body
weight ratio (Figure 6B). As can be seen in the western blot per-
formed on these muscles, accumulation of p62 in S6K1 KO
muscles is strongly reduced after rapamycin treatment (Fig-
ure 6C). Furthermore, immunohistochemistry analyses showed
no fibers containing p62-positive aggregates in the rapamycin-
treated S6K1 KO muscles (data not shown). Next, we deter-
mined muscle force in the gastrocnemius muscles after 3 weeks
of co-treatment with tamoxifen and rapamycin. As can be seen
in Figure 6D, normalized tetanic muscle force in the rapamycin-
treated Akt-S6K1 KO group is completely preserved. Taken
together, these results suggest that S6K1 is required for stimu-
lating ribosome biogenesis and preserving translation fidelity,
thereby maintaining proper muscle function during muscle
hypertrophy (Figure 6E).
DISCUSSION
The AKT-mTORC1 pathway plays a major role in muscle hyper-
trophy in response to IGF-1 signaling, as shown by the inhibitory
effect on muscle growth by rapamycin. Furthermore, this
pathway also mediates the hypertrophic effects seen after loss
of myostatin, or by overexpression of inhibitors of transforming508 Cell Reports 17, 501–513, October 4, 2016growth factor b (TGF-b) signaling, such as follistatin (Winbanks
et al., 2012). Despite this critical role of AKT-mTORC1 signaling
in regulating adult muscle mass, the downstream mediators of
this muscle hypertrophy and their functional role in adult skeletal
muscle are not known.
Here, we show that one of the main downstream effector of
mTORC1 signaling in other cell types, the kinase S6K1, is not
required for AKT-induced increases in muscle mass. Further-
more, S6K-independent muscle growth remains sensitive to ra-
pamycin, due to compensatory signaling of mTORC1 to 4E-BP1.
While S6K1 is not required for muscle growth, we find that it is
required for increasing muscle force. Muscle hypertrophy in
the absence of S6K1 is accompanied by a defective ribosome
biogenesis and formation of protein aggregates. Reducing rates
of protein synthesis by rapamycin prevents the formation of pro-
tein aggregates and leads to smaller, yet completely functional
hypertrophic muscles.
S6K1 and 4E-BP1 Can Independently Mediate
Rapamycin-Sensitive Muscle Hypertrophy
Numerous studies have shown an important role for S6K1 in the
regulation of organ size (Fenton andGout, 2011).While its role on
cell size during development has been well documented, results
obtained in adult tissues are less straight forward. As mentioned
in the introduction, the loss of S6K1/2 leads to an increase in
AMPK activation, which reduces mTORC1 signaling (Aguilar
et al., 2007). The reduction in fiber size found in S6K1/2 KO
muscles can be completely rescued by the overexpression of a
dominant-negative form of AMPK, restoring S6K-independent
mTORC1 signaling. Furthermore, overexpression of follistatin
in adult skeletal muscle, either by plasmid electroporation or
by AAV-mediated delivery, leads to a 2- to 3-fold increase in fiber
size, which requires the IGF1 receptor and is strongly reduced by
co-transfecting a dominant-negative form of AKT (Kalista et al.,
2012). Interestingly, this very significant increase in fiber size is
completely unaffected by the loss of S6K1/2. Here, we show us-
ing various approaches that S6K1/2 are not required for AKT-
induced skeletal muscle hypertrophy, due to compensatory
mTORC1 signaling to 4E-BP1.
A possible explanation for these results is that S6K1 and 4E-
BP1 compete for the binding to the core mTORC1 component
RAPTOR, which subsequently increases the mTOR-dependent,
rapamycin-sensitive phosphorylation of either S6K1 or 4E-BP1
(Hara et al., 2002). Lack of either S6K1 or 4E-BP1 signaling
would therefore lead to an increase in signaling through the
other remaining pathway, which then remains rapamycin sensi-
tive, as it depends on mTOR-RAPTOR binding. Results ob-
tained from the two knockout mice support this model in which
S6K1 and 4E-BP1 compete for RAPTOR binding. In mice lack-
ing 4E-BP1/2, an upregulation of the phosphorylation of S6K1
and S6 has been shown, possibly contributing to the insulin
resistance seen in these mice (Le Bacquer et al., 2007). On
the other hand, in S6K1 KO animals there is a slight increase
in 4E-BP1 phosphorylation (Ben-Hur et al., 2013), which is
possibly more pronounced in conditions of elevated mTORC1
signaling.
A similar competition between S6K1 and 4E-BP1 signaling
might be active during cardiomyocyte hypertrophy. Increases
Figure 5. Strong Accumulation of p62 in Akt-S6K1 KO Muscles
(A) Three weeks of AKT activation leads to a significant increase in p62-protein content in Akt-S6K1 KO muscles as compared to Akt-cre muscles.
(B) Quantification of p62 in western blotting in Akt-cre and Akt-S6K1 KO muscles after 3 weeks of AKT activation (n = 5 per group, *p < 0.001).
(C) Immunohistochemistry images for p62 show the presence of fibers containing numerous p62-positive aggregates in Akt-S6K1 KOmuscles. Staining for p62 in
Akt-cre mice only showed a diffuse staining in almost all fibers.
(D) Quantification of the number of fibers showing these p62 aggregates shows a major increase in positive fibers in Akt-S6K1 KO gastrocnemius muscles
(*p < 0.001, n = 6 muscles per group).
All data represent ± SEM.in protein synthesis by phenylephrine in cardiacmyocytes do not
require the formation of the eIF4F-complex, as the overexpres-
sion of 4E-BP1 does not have any effect (Huang et al., 2009).
Similarly, overload hypertrophy of cardiomyocytes by aortic
constriction or prolonged swimming is unaffected by the lack
of S6K1/2 (McMullen et al., 2004). Rapamycin treatment, on
the other hand, does significantly reduce cardiac hypertrophy af-
ter overloading or activation of Akt, suggesting that inhibition of
both S6K1-and 4E-BP1 signaling is sufficient to prevent cardiac
hypertrophy (Shioi et al., 2003).
We show here that inhibition of mTOR signaling to 4E-BP1 and
S6K1 is sufficient to reduce muscle growth and render it insensi-
tive to rapamycin. However, overexpression of a rapamycin-
resistant mutant of S6K1 in 4E-BP1/2 double-KO mice, which
renders both mTORC1 targets resistant to the inhibitory
effect of rapamycin, only partially prevents the inhibitory effectof rapamycin on muscle growth. The fact that rapamycin can
only partially reduce hypertrophy in this situation underlines the
importance of S6K1 and 4E-BP1 on rapamycin-sensitive muscle
growth. However, that rapamycin can still reduce muscle hyper-
trophy significantly when compared to vehicle-treated mice,
despite not being able to act on S6K1 or 4E-BP1, suggests
that there are other permissive mTOR signaling events that are
required for muscle growth. It has been shown that mTOR is
the rapamycin-sensitive mediator of overload-induced hypertro-
phy (Goodman et al., 2011), suggesting that, besides S6K1 and
4E-BP1, other mTOR-dependent signaling pathways play a role
in muscle growth. Future studies are required to address two
major open issues raised by these results: (1) which are the
additional signaling pathways involved in rapamycin-sensitive
muscle growth and (2) which are the AKT-dependent, mTOR-in-
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Figure 6. Rapamycin Treatment Prevents Muscle Myopathy in Akt-S6K1 Mice
(A) Representative blot of puromycin incorporation after treatment of Akt-cre and Akt-S6K1 KO mice for 3 weeks with tamoxifen while administering rapamycin
(2 mg/kg body weight). As can be seen in the blot, rapamycin reduces protein synthesis in both Akt-cre and Akt-S6K1 KO gastrocnemius muscles.
(B) Three weeks of AKT activation while simultaneously treating mice daily with rapamycin reduces the ratio between the weight of the gastrocnemius muscle
compared to whole-body weight (n = 12, *p < 0.005 comparing control and tam in rapamycin-treated animals; n = 12, **p < 0.01 comparing tam+vehicle and
tam+rapa).
(C) p62 content after rapamycin treatment is strongly reduced after rapamycin treatment.
(D) The loss in normalized muscle force observed in gastrocnemius muscles from Akt-S6K1 KO is completely prevented by rapamycin treatment (*p < 0.001).
(E) Scheme depicting the functional role of S6K1 in increasing muscle force during hypertrophy.
All data represent mean ± SEM.S6K1 Is Required for Ribosome Biogenesis and
Increasing Skeletal Muscle Function
The phosphorylation and activation of S6K1 occurs in almost all
forms of muscle growth and is even considered as a marker for510 Cell Reports 17, 501–513, October 4, 2016the anabolic response of muscle to resistance exercise (Terzis
et al., 2008). Since the activation of S6K1 is not required for
the increase of adult muscle mass, we investigated whether
S6K1 might be required for the induction of a functional muscle
hypertrophy. We have previously shown that activation of AKT
for 3 weeks is sufficient to induce an increase in muscle mass
and force (Blaauw et al., 2009). Despite the fact that hypertrophic
growth seen in Akt-S6K1 KOmice was similar to that seen in Akt-
cre mice, normalized muscle force in KO muscles was signifi-
cantly repressed. A possible explanation for this reduction in
muscle tension is the presence of numerous fibers with p62-pos-
itive aggregates in Akt-S6K1 KOmuscles, as it is well known that
muscles with an increase in protein aggregates show a decrease
in force production (Masiero et al., 2009). This raises the question
of how the lack of S6K1 can lead to the formation of p62-positive
aggregates. When newly synthetized proteins are truncated or
fail to fold correctly they tend to form aggresome-like induced
structures (ALIS), which require p62 for their formation (Pankiv
et al., 2007). Interestingly, the formation of these ALIS is more
pronounced in conditions in which autophagy is inhibited
(Wenger et al., 2012), as is the case for both Akt-cre and Akt-
S6K1 KO muscles. Considering that protein synthesis rates are
similar in both transgenic lines, this suggests that S6K1 influ-
ences the quality of newly formed proteins.
How can S6K1 influence protein quality and thereby muscle
force? It has been shown that S6K1 regulates the biosynthesis
of pyrimidines through the phosphorylation of the enzyme
CAD, increasing the amount of DNA or RNA, independently of
4E-BP1 signaling (Ben-Sahra et al., 2013). Indeed, here we
show that in hypertrophic Akt-S6K1 KO muscles the ratio of
RNA/DNA does not increase, possibly due to a block of CAD-
Ser1859 phosphorylation, suggesting a defective ribosome
biogenesis. This lack of ribosome biogenesis in S6K1 KO ani-
mals could potentially influence the quality of mRNA translation.
Translation is an error-prone process, with amino acid misincor-
porations occurring every 103 or 104 codons translated (Drum-
mond and Wilke, 2009). Various factors influence translation
fidelity, such as the total number of ribosomes (Belin et al.,
2009) or the speed of translational elongation. S6K1 is thought
to play an important role in both processes, namely, by stimu-
lating ribosome biogenesis (Ben-Sahra et al., 2013; Chauvin
et al., 2014) and by reducing the speed of translational elonga-
tion (Conn and Qian, 2013). It is tempting to assume that skeletal
muscle, which requires the synthesis of multiple large sarco-
meric proteins for muscle growth, is particularly sensitive to
changes in translation speed and fidelity. Indeed, in a model of
synergist ablation, where muscle undergoes an explosive in-
crease in size, there is a very significant increase in ribosome
biogenesis (Goodman et al., 2011; Kirby et al., 2015), possibly
to sustain elevated rates of protein synthesis while maintaining
protein quality. Future studies evaluating the content of the pro-
tein aggregates, and how these induce muscle dysfunction, will
help to better understand in which way the presence of aggre-
gates can impinge on muscle force.
Overall, these results suggest that in conditions of increased
protein synthesis, activation of S6K1 is necessary to increase
ribosome biogenesis and therefore maintain protein quality and
muscle force.
Conclusions
The data reported here show that S6K1 and mTOR-depen-
dent phosphorylation of 4E-BP1 can independently mediateAKT-induced muscle hypertrophy. Importantly, we show that
they are two key targets downstream of mTOR for the inhibitory
effect of rapamycin, a drug that inhibits most forms of muscle hy-
pertrophy. The importance of S6K1 in maintaining muscle force
during hypertrophy underlines the importance of better under-
standing not only the signaling pathways regulating muscle
mass, but also the signaling pathways involved in the regulation
of muscle force production. In certain muscular dystrophies, or
during aging, a pivotal part of the pathology is due to the reduc-
tion in specific force, not just reduced muscle mass.
EXPERIMENTAL PROCEDURES
Transgenic Mice/Treatments
Generation of S6K1/2-deficient mice (C56BL/6-129/Ola) and S6K1 KO mice
(C57BL/6) has been previously described (Pende et al., 2004). The generation
of Akt-Cre transgenic mice was described previously (Blaauw et al., 2008,
2009). We crossed this Akt-Cre line with S6K1 KO mice in order to obtain
the Akt-S6K1 KO mice. To activate AKT, animals were treated with 1 mg of
tamoxifen dissolved in sunflower oil once every other day. Each genotype
was compared with Cre-negative animals of the same genetic background in-
jected with tamoxifen. Mice lacking 4E-BP1 and 4E-BP2 were described pre-
viously (Le Bacquer et al., 2007). Rapamycin treatment was performed by
intraperitoneal injections at 2 mg/kg body weight every day. Puromycin was
injected i.p. with 0.04 mmol/g puromycin exactly 30min before removal ofmus-
cles. Muscle homogenates were processed for western blot analysis using an
antibody specific for puromycin. Experimental protocols were reviewed and
approved by the local Animal Care Committee, University of Padova.
Plasmid Constructs
We used hemagglutinin (HA)-tagged plasmid constructs to overexpress myr-
AKT (Pallafacchina et al., 2002) and 4E-BP1-4A, mutated on the first four
mTORC1-dependent phosphorylation sites (Yanagiya et al., 2012). The se-
quences used for knocking down S6K1/2 were described previously (Aguilar
et al., 2007). The selected oligos were cloned into the pSUPER vector. We co-
transfected a plasmid coding for Snap-GFP together with the pSUPER. As a
control, we used pSUPER constructs targeting LacZ. The plasmid expressing
a rapamycin-resistant mutant of S6K1 has been described previously (Ohanna
et al., 2005).
In Vivo Electroporation
Adult mice were used in all experiments. TA muscles were transfected as
described previously (Tothova et al., 2006). Muscles were analyzed 7 or
10 days after electroporation.
Antibodies for Western Blot and Immunohistochemistry
We used the following antibodies for immunohistochemistry; laminin from
Sigma, Phospho-S6 from Cell Signaling Technology, HA from Santa Cruz
Biotechnology, and embryonicMyHC fromDevelopmental Studies Hybridoma
Bank. For western blotting, P-AKT (S473), P-AKT (T308), P-S6 (S240/244), S6,
S6K1, AKT, GSK-3b, P-GSK-3b (S9), 4E-BP1, RAPTOR, P-mTOR (S2448),
mTOR, P-CAD (S1859), P-AMPK (T172), and AMPK were from Cell Signal,
P62 was from Sigma, GAPDH was from Abcam, actin was from Santa Cruz,
and puromycin from Millipore.
Histology
Cryosections of the TA and gastrocnemius muscles after electroporation, in
wild-type animals, and S6K1 and S6K1/2 KO animals were examined by
fluorescence microscope. Cross-sectional area was measured for TA as
described previously (Pallafacchina et al., 2002) and compared with the area
of surrounding non-transfectedmyofibers. Cross-sectional area of transfected
fibers wasmeasured in at least fivemuscles per group. Cryosections of TA and
gastrocnemius muscles were stained for H&E and for succinate dehydroge-
nase in Akt-Cre and Akt-S6K1 KO animals.Cell Reports 17, 501–513, October 4, 2016 511
In Vivo Muscle Mechanics
Force measurements performed in vivo on the gastrocnemius muscle were
described elsewhere (Blaauw et al., 2009). Briefly, in vivo gastrocnemius
muscle contractile performance was measured using a 305B muscle lever
system (Aurora Scientific) in mice anaesthetized with a mixture of Xylotine
and Zoletil.
RNA-DNA and Ribosomal RNA Quantification
The TA muscle was homogenized in 1 mU of a basic phenol/chloroform buffer
to separate nucleic acids. RNA and DNA content were determined using spe-
cific fluorescent dyes selective for RNA (Qubit RNA Assay Kits, Invitrogen) or
double-stranded DNA (Qubit dsDNA HS Assay Kits, Invitrogen), respectively.
Measurements were realized using Qubit 2.0 fluorometer (Invitrogen). In order
to highlight changes in rRNA content occurring during the 3-week treatment
period, we used mice with exactly the same body weight before starting
tamoxifen treatment. Next, we homogenized whole muscles in the same vol-
ume and loaded 10 ml of the RNA solution on a 1% agarose gel and viewed
it under UV light. Densitometric measurements of the 28S and 18S ribosomal
RNA (rRNA) were performed with ImageJ software.
Statistics
All data are expressed as means ± SEMs. Differences between groups were
assessed using Student’s t test or one-way ANOVA. Significance was defined
as a p value of less than 0.05 (95% confidence).
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